RecruitingNot ApplicableNCT07637266

Impact of Del Nido Versus Blood Cardioplegia on Myocardial Viability Assessed With Magnetic Resonance Imaging


Sponsor

Klinički Bolnički Centar Zagreb

Enrollment

60 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Myocardial protection during surgical myocardial revascularization is crucial for reducing perioperative myocardial injury and improving postoperative outcomes. Blood cardioplegia represents the standard method in many centers, while del Nido cardioplegia, originally developed for the pediatric population, is increasingly being used in adult patients as well.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Blood Cardioplegia Solution for myocardial protection and a drug called Del Nido Cardioplegia Solution for myocardial protection for people with cabg and myocardial viability. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDel Nido Cardioplegia Solution for myocardial protection

CABG patients receiving Del Nido cardioplegia as the myocardial protection strategy

DRUGBlood Cardioplegia Solution for myocardial protection

Patients will receive Blood Cardioplegia Solution for myocardial protection


Locations(2)

University Hospital Center Zagreb

Zagreb, Croatia

University Hospital Center Zagreb

Zagreb, Croatia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07637266


Related Trials